Rick has over 20 years of strategic marketing and sales experience in the medical device industry. We look forward to the contributions he will make as we continue to penetrate the market with the Visica 2™ Treatment System.
Pleasanton, CA (PRWEB) March 29, 2016
Sanarus Technologies, Inc., a medical device company that develops and manufactures cryoablation systems for the minimally invasive treatment of early stage breast tumors, today announced the appointment of Rick Stark to its board of directors. Mr. Stark will join current board members BJ Hardman (Chairman), Dr. Frank Facchini, Charles Berolzheimer, Lee Story, Matt Nalipinski, Sharon Maher and Sterling Lanier.
“We are delighted to have Rick join the Sanarus team,” said BJ Hardman, Chief Executive Officer and Chairman. “Rick has over 20 years of strategic marketing and sales experience in the medical device industry, and we look forward to the contributions he will make as we continue to penetrate the market with the Visica 2™ Treatment System.”
In his current role as senior vice president, general manager at AngioDynamics, Mr. Stark has been instrumental in the development and commercialization of the company’s portfolio. From 1999 to 2012, he served as vice president of sales and marketing for the company’s oncology/surgery division. He has extensive experience in shaping corporate strategy and is skilled in all aspects of corporate startup, growth and acquisition. Prior to his tenure at AngioDynamics, he was district sales manager for RITA Medical. He has also held field sales positions at Woodside Biomedical and Arrow/Teleflex.
“I’m pleased to have the opportunity to advance market adoption of this innovative technology,” said Stark. “I look forward to working closely with the board and management team in this stage of the company’s growth, and beyond.”
The Visica 2 Treatment System uses extreme cold to destroy tissue. The patented, FDA-cleared system destroys the tumor by freezing it with liquid nitrogen and damaging the adjacent blood supply that fuels tumor growth. Cryoablation offers benefits over surgery, i.e., the procedure is done under local anesthesia, no breast tissue is removed and the shape of the breast is maintained. Leading breast surgeons and interventional radiologists are using this advanced technology for the treatment of breast tumors as an alternative to surgical lumpectomy.
About Sanarus Technologies, Inc.
In 2001, the Visica® Treatment System was the first system available for cryoablation of fibroadenomas. Since then, our systems have been used to successfully treat thousands of patients. The System is FDA-cleared for the ablation of cancerous or malignant tissue and benign tumors. Since 2007, the Visica 2 Treatment System has been used to treat cancer in hundreds of cryoablation-assisted surgeries and dozens of cryoablation-only procedures in clinical trials. At Sanarus, we pride ourselves in developing innovative solutions for the nonsurgical treatment of breast tumors. We are a woman-owned business, headquartered in Pleasanton, CA, and all of our products are manufactured in the USA. Find out more at http://www.sanarus.com.